Please use this identifier to cite or link to this item:
Title: Age of Red Cells for Transfusion and Outcomes in Critically Ill Adults
Authors: Cooper, D James;McQuilten, Zoe K;Nichol, Alistair;Ady, Bridget;Aubron, Cécile;Bailey, Michael;Bellomo, Rinaldo;Gantner, Dashiell;Irving, David O;Kaukonen, Kirsi-Maija;McArthur, Colin;Murray, Lynne;Pettilä, Ville;French, Craig;TRANSFUSE Investigators;Australian and New Zealand Intensive Care Society Clinical Trials Group
Issue Date: Nov-2017
EDate: 2017-09-27
Citation: New England Journal of Medicine 2017; 377: 1858-1867
Abstract: BACKGROUND: It is uncertain whether the duration of red-cell storage affects mortality after transfusion among critically ill adults. METHODS: In an international, multicenter, randomized, double-blind trial, we assigned critically ill adults to receive either the freshest available, compatible, allogeneic red cells (short-term storage group) or standard-issue (oldest available), compatible, allogeneic red cells (long-term storage group). The primary outcome was 90-day mortality. RESULTS: From November 2012 through December 2016, at 59 centers in five countries, 4994 patients underwent randomization and 4919 (98.5%) were included in the primary analysis. Among the 2457 patients in the short-term storage group, the mean storage duration was 11.8 days. Among the 2462 patients in the long-term storage group, the mean storage duration was 22.4 days. At 90 days, there were 610 deaths (24.8%) in the short-term storage group and 594 (24.1%) in the long-term storage group (absolute risk difference, 0.7 percentage points; 95% confidence interval [CI], -1.7 to 3.1; P=0.57). At 180 days, the absolute risk difference was 0.4 percentage points (95% CI, -2.1 to 3.0; P=0.75). Most of the prespecified secondary measures showed no significant between-group differences in outcome. CONCLUSIONS: The age of transfused red cells did not affect 90-day mortality among critically ill adults. (Funded by the Australian National Health and Medical Research Council and others; TRANSFUSE Australian and New Zealand Clinical Trials Registry number, ACTRN12612000453886 ; number, NCT01638416 .).
DOI: 10.1056/NEJMoa1707572
ORCID: 0000-0002-1650-8939
PubMed URL:
Type: Journal Article
Subjects: Blood Preservation
Erythrocyte Transfusion/mortality
Critical Illness/therapy
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.